Corporate Profile for LifeCell Corporation, dated December 4, 1998.

--(BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services.

-0-

Published Date:   December 4, 1998

Company Name:     LifeCell Corporation

Address:          3606 Research Forest Drive
                  The Woodlands, Texas 77381

Main Telephone
 Number:          281/367-5368

Internet Home
 Page Address
  (URL)           www.lifecell.com

Chief Executive
 Officer:         Paul G. Thomas

Investor Relations
 Contact:         Rebecca L. Elliott
 Business number: 281/367-5368

Public Relations
 Contact:         Rebecca L. Elliott
 Business number: 281/367-5368

Trading Symbol/
 Exchange:        LIFC/Nasdaq

Industry:         Healthcare: Medical Technology and Device,
                  Biomedical

Market Makers:    Vector Securities International, Gruntal & Co.,
                  Harris, Webb & Garrison, Troster Singer, Mayer &
                  Schweitzer

Company description: LifeCell Corporation (Nasdaq:LIFC) is a bioengineering company engaged in the development and commercialization of tissue regeneration and cell preservation products. The Company's patented core technology serves as platforms for a broad range of potential products addressing significant clinical needs in multiple markets.

LifeCell's first commercial product is AlloDerm(R), an extracellular tissue matrix that retains the essential biochemical and structural composition of human dermis. When transplanted to a patient, the AlloDerm dermal matrix is incorporated into the surrounding tissue and is repopulated with the patient's own cells. Moreover, AlloDerm guides the new cells to remodel and maintain the matrix, establishing a new functional living tissue. AlloDerm is the only commercial tissue transplant product that promotes normal human soft tissue regeneration. It is marketed and sold for use in reconstructive plastic, dental and burn surgery. Since the commercial introduction of AlloDerm grafts in late 1994, more than 30,000 patients have been treated with AlloDerm tissue products.

In addition to AlloDerm, the Company's current tissue graft development programs include the LifeCell(R) heart valve, vascular grafts and nerve connective tissue. LifeCell's product development programs also include ThromboSol(TM), a formulation for extending the shelf life of transfusable platelets, and technologies to enhance the storage of red blood cells, granulocytes and stem cells.

LifeCell was founded in 1986 and is headquartered in The Woodlands, Texas. For additional information about the company, visit LifeCell's web site at http://www.lifecell.com.

-0-

As of September 30, 1998:
Ticker Symbol (Nasdaq):           LIFC
Current Price:                    $3.938
52-week high/low                  $3.25-8.375
Market Capitalization:            $59.5 million
Common Shares Outstanding:        11.3 million
Common Equivalent of Preferred
 Stock Outstanding:               3.8 million
Total Common Equivalent
 Shares Outstanding:              15.1 million

Cash and Short-term
Investments:                      $14 million
Long-term Debt:                   None
Product Sales:
Year ended December 31, 1997:     $6.0 million
First Nine months 1998:           $5.8 million
Net Income/Loss:
Year ended December 31, 1997:     $6.1 million
First Nine months 1998:           $4.6 million

-0-